• Vivoryon Therapeutics' net loss narrowed 37% year-over-year to EUR 4.8 million in the nine months ended September 30, 2026.
• Research and development expenses fell 38% to EUR 2.3 million, largely due to lower clinical development and analysis costs for kidney research.
• Cash and cash equivalents totaled EUR 1.7 million at September 30, 2026, versus EUR 5.6 million at December 31, 2025.
• Negotiations continue for a partnership or financing to advance varoglutamstat into a Phase 2b kidney disease study; alternatives include a company sale.
• Additional cost savings extended the expected cash runway into the second half of December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050100OMX_____CNEWS_EN_GNW1001301861_en) on November 05, 2026, and is solely responsible for the information contained therein.